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BACKGROUND. The American Cancer Society (ACS), the Centers for Disease Control
and Prevention (CDC), the National Cancer Institute (NCI), and the North Amer-
ican Association of Central Cancer Registries (NAACCR) collaborate annually to
provide updated information regarding cancer occurrence and trends in the U.S.
This year’s report features a special section on cancer survival.
METHODS. Information concerning cancer cases was obtained from the NCI, CDC,
and NAACCR and information concerning recorded cancer deaths was obtained
from the CDC. The authors evaluated trends in age-adjusted cancer incidence and
death rates by regression models and described and compared survival rates over
time and across racial/ethnic populations.
RESULTS. Incidence rates for all cancers combined decreased from 1991 through
2001, but stabilized from 1995 through 2001 when adjusted for delay in reporting.
The incidence rates for female lung cancer decreased (although not statistically
significant for delay adjusted) and mortality leveled off for the first time after
increasing for many decades. Colorectal cancer incidence rates also decreased.
Death rates decreased for all cancers combined (1.1% per year since 1993) and for
many of the top 15 cancers occurring in men and women. The 5-year relative
survival rates improved for all cancers combined and for most, but
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not all, cancers over 2 diagnostic periods (1975–1979 and 1995–2000). However,
cancer-specific survival rates were lower and the risk of dying from cancer, once
diagnosed, was higher in most minority populations compared with the white
population. The relative risk of death from all cancers combined in each racial and
ethnic population compared with non-Hispanic white men and women ranged
from 1.16 in Hispanic white men to 1.69 in American Indian/Alaska Native men,
with the exception of Asian/Pacific Islander women, whose risk of 1.01 was similar
to that of non-Hispanic white women.
CONCLUSIONS. The continued measurable declines for overall cancer death rates
and for many of the top 15 cancers, along with improved survival rates, reflect
progress in the prevention, early detection, and treatment of cancer. However,
racial and ethnic disparities in survival and the risk of death from cancer, and
geographic variation in stage distributions suggest that not all segments of the U.S.
population have benefited equally from such advances. Cancer 2004;101:3–27.
Published 2004 by the American Cancer Society.*
KEYWORDS: cancer; incidence; mortality; survival; Surveillance, Epidemiology, and
End Results (SEER); National Program of Cancer Registries (NPCR); North American
Association of Central Cancer Registries (NAACCR); vital statistics; U.S.
The American Cancer Society (ACS), the Centers forDisease Control and Prevention (CDC), the Na-
tional Cancer Institute (NCI), and the North American
Association of Central Cancer Registries (NAACCR)
collaborate each year to produce an annual report to
the nation regarding the current status of cancer in the
U.S. The initial report in 1998 documented the first
sustained decline in cancer death rates since national
record-keeping was instituted in the 1930s.1 Subse-
quent reports generally confirmed this finding and
provided updates.2– 6 Last year’s report focused on the
use of surveillance data for cancer control. The current
report provides incidence and mortality data for all
cancers and the top 15 cancers among all races com-
bined and in each major racial/ethnic population
(whites, blacks, Asians/Pacific Islanders [API], Ameri-
can Indians/Alaska Natives [AI/AN], and Hispanics/
Latinos). It also features a special section concerning
cancer survival over time and by race/ethnicity (non-
Hispanic whites, Hispanic whites, blacks, API, and
AI/AN).
MATERIALS AND METHODS
Cancer Cases and Deaths
Information regarding newly diagnosed cancer cases
in the U.S. is based on data collected by cancer regis-
tries participating in the NCI’s Surveillance, Epidemi-
ology, and End Results (SEER) Program or the CDC’s
National Program of Cancer Registries (NPCR). All reg-
istries are members of the NAACCR.7 With the excep-
tion of bladder cancer, the data regarding incidence
refer to invasive but not in situ cancers. Beginning
with incident cases in 2001, all information concern-
ing primary cancer site and histology was coded ac-
cording to the third edition of the International Clas-
sification of Diseases for Oncology (ICD-O)8 and
categorized according to SEER site groups.9 To ensure
as much comparability as possible between the sec-
ond and third revisions of the ICD-O, the following
inclusions/exclusions were made: borderline tumors
of the ovary, refractory anemias, and other myelodys-
plastic syndromes were excluded, whereas pilocytic
astrocytomas were included. The site/histology cate-
gories presented for childhood survival are based on
site first and then histology to be more comparable to
the adult cancers; therefore, this listing is not equiva-
lent to the International Classification of Childhood
Cancer.10 We defined childhood as age  20 years.
When applicable, cancer cases were staged as either
localized, regional, distant, or unknown according to
SEER Summary Stage 1977.11,12 Cases identified by
death certificate or autopsy only were excluded from
staging and survival.
Cancer deaths in the U.S., reported to state vital
statistics offices and consolidated into a database by
the CDC, through the National Vital Statistics Sys-
tem,13 were coded according to the version of the
International Classification of Diseases (ICD) in use in
the U.S. at the time of death.14 –16 Beginning with 1999
mortality data, the tenth revision of the ICD (ICD-10)
was used to code the cause of death. Under ICD-10
rules, cancer was slightly more likely to be selected as
the underlying cause of death than under previous
ICD rules.17 Sites were grouped by SEER to allow for
maximum comparability between versions of ICD
codes.9
For the long-term trend analyses of the rates for
all cancers and the 15 most common cancers among
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all races/ethnicity combined, we used SEER incidence
data from the 9 original registries (covering approxi-
mately 10% of the U.S. population)18 and U.S. mortal-
ity data for 1975–2001. For the short-term trend anal-
yses of the incidence and death rates for the 15 most
common cancers in each major racial and ethnic pop-
ulation (whites, blacks, API, AI/AN, and Hispanics/
Latinos), we used incidence data from 12 SEER cancer
registries (covering approximately 14% of the U.S.
population, including 12% of whites, 12% of blacks,
36% of API, 21% of AI/AN, and 22% of Hispanics/
Latinos) and 100% of the U.S. population for cancer
mortality data for 1992–2001. We examined incidence
data for 23 cancers and mortality data for 22 cancers
to accommodate the top 15 cancers for incidence rates
and for death rates in each racial and ethnic popula-
tion. Information regarding cancer incidence and
death is collected on groups within the API and His-
panic/Latino populations but rates cannot be calcu-
lated because of the lack of intercensal county popu-
lation estimates from the U.S. Census Bureau.
Changes in survival rates over time were exam-
ined for the top 15 cancers in males and females and
for cancers common in children and adolescents (ages
birth–19 years) using cancer cases diagnosed during
1975–1979 and 1995–2000 in the 9 SEER areas. For
describing and comparing cancer survival rates
among racial and ethnic populations, cancer cases
diagnosed between 1992–2000 in the 12 SEER areas
were used. For assessing geographic variations in
stage distribution for cancers of the colon/rectum,
female breast, cervix uteri, and prostate, we used in-
cidence data reported to the NAACCR from 29 SEER
and NPCR registries for 1996 –2000 that met NAACCR
criteria for high quality incidence data as of December
2003, covering 43% of the U.S. population.
Cancer Incidence and Death Rates
Rates were age-adjusted to the 2000 U.S. standard
million population and expressed per 100,000 popu-
lations by use of population estimates from the U.S.
Census Bureau. Estimates of rates, standard errors,
and 95% confidence intervals were generated using
SEER*Stat software.18
Statistical Analysis
The long-term trends (1975–2001) in cancer incidence
and death rates among all races combined were de-
scribed by joinpoint regression analysis, which in-
volves fitting a series of joined straight lines on a log
scale to the trends in the age-adjusted rates.19 The
resultant trends of varying time periods were de-
scribed by annual percent change (i.e., the slope of the
line segment). We present the incidence trends based
on both the observed data and data with reporting
adjustment. Reporting adjustment refers to the adjust-
ment for the late arrival of new cancer cases to cancer
registries after the standard reporting period for a
diagnosis year as well as to changes and updates of
data items such as demography and tumor character-
istics for previously reported cases. This adjustment,
which will be referred to as delay adjustment hereaf-
ter, is important because the most recent diagnosis
year will have the largest underreporting of cases, with
smaller amounts of underreporting for earlier diagno-
sis years. We use statistical models to adjust the cur-
rent cancer count to account for anticipated future
improvements to the data based on observed patterns
in SEER registries.20 Delay adjustment may affect the
interpretation of current trends, especially for cancers
frequently diagnosed in nonhospital settings such as
melanoma, breast cancer, and prostate cancer. How-
ever, descriptions of long-term trends in the text are
based on the observed data, except when specifically
noted. For the short-term trend analyses in each racial
and ethnic population, annual percent changes for a
fixed time period (1992–2001) were estimated by fit-
ting a linear regression line to the natural logarithms
of the rates using calendar year as the independent
variable.3 In describing trends, the terms “increase” or
“decrease” were used when the slope (coefficient) of
the trend was statistically significant (two-sided P
 0.05) and the terms “stable” or “level” were used
otherwise.
Changes in the 5-year relative survival rates for the
top 15 cancers and childhood cancers were examined
by a life table method for cases diagnosed between
1975–1979 and 1995–2000 and followed for vital status
through December 31, 2001. We compared survival
rates between these two periods by calculating abso-
lute (1995–2000 rate minus 1975–1979 rate) and pro-
portional (absolute change divided by the 1975–1979
rate) changes. Survival rates by race/ethnicity for the
23 cancers were described using cancer-specific sur-
vival rates instead of relative survival rates because
reliable expected life tables are not available for the
Hispanic white, AI/AN, and API populations to gener-
ate valid relative survival estimates. The Kaplan–Meier
estimator21 was used to estimate the 5-year cancer-
specific survival. Both relative and cause-specific sur-
vival rates provide an estimate of the likelihood of
surviving 5 years if the index cancer was the only cause
of death, although the estimation methods differ as
described elsewhere.22 Differences in cancer survival
among racial and ethnic populations (with non-His-
panic whites as the reference group) were assessed by
computing relative risks (RRs) (i.e., hazard ratios) of
cancer death, after controlling for age (all sites, brain
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cancer, myeloma, and leukemia) or controlling for
both age and tumor stage at the time of diagnosis
(remaining sites) using Cox regression models, with a
maximum of 5 years of follow-up.23 Stratified Cox
models were used to avoid the assumption of propor-
tional hazards for age and tumor stage. SAS statistical
software was used in the analysis, with two-sided P
values  0.05 considered to indicate statistical signif-
icance.24 Note that the duration of survival was mea-
sured from date of diagnosis and that cases identified
by death certificate or autopsy only were excluded
from survival analyses because the survival duration
was unknown or not applicable.
Additional data concerning cancer incidence and
mortality are available from the following URL ad-
dresses: www.cancer.org (ACS); www.cdc.gov/cancer/
npcr/index.htm and www.cdc.gov/nchs/about/major/
dvs/mortdata.htm (CDC); and www.naaccr.org/CINAP/
index.htm (NAACCR).
RESULTS
Update on the Long-Term Incidence Trends for All
Cancers Combined and the Top 15 Cancer Sites for All
Races
Overall cancer incidence rates for all racial and ethnic
populations combined declined by 0.5% per year be-
tween 1991–2001 but stabilized between 1995–2001
when adjusted for delay in reporting (Table 1). Inci-
dence rates for all cancers combined stabilized from
1995–2001 both in men and in women, but these rates
increased in women by 0.3% per year since 1987 when
adjusted for delay in reporting. For males, cancer in-
cidence rates increased during the last time segment
for prostate cancer, melanoma of the skin (mela-
noma), kidney and renal pelvis (kidney) cancer, and
cancer of the esophagus and remained the same for
urinary bladder (bladder) cancer, non-Hodgkin lym-
phoma (NHL), liver and intrahepatic bile duct (liver)
cancer, and brain and other nervous system (brain)
cancers. Incidence declined for the remaining top 15
cancer sites, which include lung and bronchus (lung),
colon/rectum, oral cavity and pharynx (oral cavity),
leukemia, stomach, pancreas, and larynx. When rates
were adjusted for delayed reporting, the directions of
trend changed, with a significant increase noted for
bladder cancer and a stabilized trend for leukemia and
pancreatic cancer reported. The incidence rates for
prostate cancer have had large fluctuations in trend.
Rates increased 2.6% per year between 1975–1988 with
a more dramatic increase of 16.4% per year between
1988 –1992. Between 1992–1995, rates decreased by
11.4% per year, followed by a much smaller increase of
1.4% per year from 1995 through 2001.
For females, increases in incidence among the top
15 cancers were limited to breast cancer, melanoma,
thyroid cancer, bladder cancer, and kidney cancer.
Female breast cancer increased 0.4% per year between
1987–2001, which is a slower rate of increase com-
pared with that of the previous time period (1980 –
1987) of 3.7% per year. Trends in the remaining sites
were declining or stable, except the NHL trend, which
increased by 1.1% per year when rates were adjusted
for delayed reporting. The increase in female lung
cancer incidence slowed from 4.6% per year between
1975–1988 to 1.3% from 1988 –1998, and most impor-
tant, recently declined (1998 –2001), although stabiliz-
ing rather than declining when rates were adjusted for
reporting delay. Female colorectal cancer rates de-
clined rapidly between 1985–1995, and then had a
short period of stabilization followed by a recent
(1998 –2001) decline of 2.8% per year.
Update on the Long-Term Mortality Trends for All
Cancers Combined and the Top 15 Cancer Sites for All
Races
Overall cancer death rates for all racial and ethnic
populations combined decreased by 1.1% per year
from 1993–2001, with the decline found to be more
pronounced in men (1.5% per year from 1993–2001)
than in women (0.8% per year from 1992–2001) (Table
2). Mortality trends for the top 15 cancers differed
slightly between men and women. Death rates de-
creased for 11 of the top 15 cancers in men and for 8
of the top 15 cancers in women. Rates increased for
esophageal cancer (0.5% per year between 1994 –2001)
and liver cancer (1.4% per year between 1995–2001) in
males, but for none of the top 15 cancers in females.
Death rates leveled off for kidney cancer and mela-
noma in men and for 7 of the top 15 cancers in
women. It is interesting to note that female lung can-
cer death rates between 1995–2001 leveled off for the
first time after continuously increasing for many dec-
ades. Age-adjusted female lung cancer death rates
(deaths per 100,000 females) were virtually unchanged
in the last 5 years (40.3 in 1995 and 40.9 in 2001), in
contrast with the greater than 2-fold increase reported
from 17.6 in 1975 to 39.3 in 1994.
Incidence and Mortality by Race and Ethnicity (Whites,
Blacks, API, AI/AN, and Hispanics/Latinos) between
1992–2001
The 15 most frequently occurring cancers by sex for
incidence and mortality between 1992–2001 were
ranked for all races combined and for each racial and
ethnic population separately (Tables 3 and 4). Among
men, cancers of the prostate, lung, and colon/rectum
were the three most common incident cancers in rank
order for every racial and ethnic population, except His-
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TABLE 1
SEER Incidence Rate Trends with Joinpointa Analyses for 1975 through 2001 for the Top 15 Cancers,b All Races
Joinpoint analyses (1975–2001)c
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
All sitese
Both sexes 1975–1983 0.9f 1983–1991 1.8f 1991–2001 0.5f
(Delay-adjusted) 1975–1989 1.2f 1989–1992 2.8 1992–1995 2.1 1995–2001 0.4
Male 1975–1989 1.3f 1989–1992 5.1f 1992–1995 4.6f 1995–2001 0.2
(Delay-adjusted) 1975–1989 1.3f 1989–1992 5.2f 1992–1995 4.7f 1995–2001 0.2
Female 1975–1979 0.2 1979–1987 1.5f 1987–1999 0.3f 1999–2001 1.8
(Delay-adjusted) 1975–1979 0.2 1979–1987 1.5f 1987–2001 0.3f
Top 15 for males
Prostate 1975–1988 2.6f 1988–1992 16.4f 1992–1995 11.4f 1995–2001 1.4f
(Delay-adjusted) 1975–1988 2.6f 1988–1992 16.5f 1992–1995 11.5f 1995–2001 2.0f
Lung and bronchus 1975–1982 1.5f 1982–1992 0.5f 1992–2001 2.2f
(Delay-adjusted) 1975–1982 1.4f 1982–1991 0.4 1991–2001 1.9f
Colon and rectum 1975–1986 1.1f 1986–1995 2.1f 1995–1998 1.0 1998–2001 3.5f
(Delay-adjusted) 1975–1986 1.1f 1986–1995 2.1f 1995–1998 1.1 1998–2001 2.9f
Urinary bladder 1975–1987 0.9f 1987–2001 0.1
(Delay-adjusted) 1975–1987 1.0f 1987–1995 0.5 1995–2001 0.9f
Non-Hodgkin lymphoma 1975–1991 4.3f 1991–2001 0.1
(Delay-adjusted) 1975–1991 4.3f 1991–2001 0.1
Melanoma of the skin 1975–1985 5.6f 1985–2001 3.1f
Oral cavity and pharynx 1975–1993 0.7f 1993–2001 2.8f
Leukemia 1975–1988 0.2 1988–2001 0.7f
(Delay-adjusted) 1975–2001 0.1
Kidney and renal pelvis 1975–1987 2.3f 1987–2001 1.2f
(Delay-adjusted) 1975–2001 1.8f
Stomach 1975–1989 1.2f 1989–2001 2.2f
(Delay-adjusted) 1975–1988 1.1f 1988–2001 2.1f
Pancreas 1975–1978 2.8 1978–2001 0.5f
(Delay-adjusted) 1975–1993 0.8f 1993–2001 0.2
Liver and intrahepatic bile duct 1975–1984 1.7 1984–1999 4.5f 1999–2001 4.9
(Delay-adjusted) 1975–1984 1.7 1984–1999 4.6f 1999–2001 2.7
Brain and other nervous system 1975–1989 1.2f 1989–2001 0.5
(Delay-adjusted) 1975–1989 1.2f 1989–2001 0.3
Esophagus 1975–2001 0.8f
(Delay-adjusted) 1975–2001 0.8f
Larynx 1975–1988 0.2 1988–2001 2.8f
Top 15 for females
Breast 1975–1980 0.4 1980–1987 3.7f 1987–2001 0.4f
(Delay-adjusted) 1975–1980 0.4 1980–1987 3.7f 1987–2001 0.5f
Lung and bronchus 1975–1988 4.6f 1988–1998 1.3f 1998–2001 2.3f
(Delay-adjusted) 1975–1982 5.5f 1982–1990 3.5f 1990–1998 1.1f 1998–2001 1.3
Colon and rectum 1975–1985 0.3f 1985–1995 1.9f 1995–1998 1.7 1998–2001 2.8f
(Delay-adjusted) 1975–1985 0.3f 1985–1995 1.9f 1995–1998 1.8 1998–2001 2.3f
Corpus and uterus, NOS 1975–1979 6.0f 1979–1988 1.7f 1988–1998 0.6f 1998–2001 1.5
Non-Hodgkin lymphoma 1975–1988 3.0f 1988–1998 1.5f 1998–2001 1.6
(Delay-adjusted) 1975–1990 2.9f 1990–2001 1.1f
Ovarye 1975–1985 0.2 1985–2001 0.8f
(Delay-adjusted)e 1975–1985 0.2 1985–2001 0.7f
Melanoma of the skin 1975–1981 5.1f 1981–2001 2.2f
Cervix uteri 1975–1982 4.6f 1982–1990 0.2 1990–2001 2.5f
(Delay-adjusted) 1975–1982 4.5f 1982–1990 0.2 1990–2001 2.4f
Pancreas 1975–1984 1.4f 1984–2001 0.4f
(Delay-adjusted) 1975–1984 1.3f 1984–2001 0.3f
(continued)
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panics/Latinos, for whom colorectal cancer ranked
ahead of lung cancer (Table 3). The same three sites
(with lung first and prostate second) were the leading
causes of cancer death among men in each population,
except in API men, in whom colon/rectum and liver
cancers ranked second and third, respectively (Table 4).
Among women, the three leading cancer sites in rank
order for incidence in each racial and ethnic population
were breast, colon/rectum, and lung, except in white
women, in whom lung cancer ranked second (Table 3).
The same three sites (with lung first and breast second)
were the leading causes of cancer death among women
in each population, except Hispanic/Latina women,
whose death rates for breast cancer were higher than for
cancer of the lung (Table 4).
Examination of short-term trends in incidence by
race and ethnicity between 1992–2001 revealed that
rates for lung and prostate cancer were decreasing
among men in all populations, except API men (only
lung decreasing); colorectal cancer rates were decreas-
ing only for white and API men (Table 3). Among
females, breast cancer incidence rates were increasing
in white and API women and were decreasing among
AI/AN women; lung cancer rates also were decreasing
in AI/AN women and were stable for the other popu-
lations.
Incidence trends for other cancer sites also varied
by race/ethnicity and sex (Table 3). Trends for many
sites cannot be examined among AI/AN men and
women because of small numbers; these sites are not
noted in the results. Among men, declines in stomach
cancer and nonepithelial skin cancers were observed
in all populations; cancers of the oral cavity and larynx
also were reported to decrease in all populations ex-
cept among API men. Cervical cancer rates were re-
portedly decreasing for women of all racial and ethnic
populations except AI/AN women (annual percent
change  -7.0; P  0.05). Thyroid cancer rates were
increasing among white, black, and Hispanic/Latina
women, and kidney cancer increased among women
of all racial and ethnic populations except among
AI/AN women.
Analyses of short-term mortality trends revealed
that death rates decreased in men for cancers of the
lung, prostate, and colon/rectum in each racial and
ethnic population, except for the lung in AI/AN men
and the colon/rectum in AI/AN and Hispanic/Latino
men (Table 4). Among women, death rates decreased
for colorectal cancer in white, black, and API women
and for breast cancer in white, black and Hispanic/
Latina women, whereas rates increased for lung can-
cer in white women.
Mortality trends for cancer sites other than the top
three sites also varied by race/ethnicity and sex (Table 4).
Death rates for esophageal cancer increased among
white men between 1992–2001 and decreased among
black and Hispanic/Latino men. Stomach cancer death




Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
Leukemia 1975–2001 0.1
(Delay-adjusted) 1975–1999 0.2f 1999–2001 5.0
Thyroid 1975–1981 1.3 1981–1993 2.1f 1993–2001 4.5f
Urinary bladder 1975–2001 0.2f
(Delay-adjusted) 1975–2001 0.2f
Kidney and renal pelvis 1975–1992 2.7f 1992–2001 1.1f
(Delay-adjusted) 1975–2001 2.3f
Oral cavity and pharynx 1975–1980 2.6f 1980–2001 1.0f
Stomach 1975–1996 1.9f 1996–1999 2.4 1999–2001 9.0
(Delay-adjusted) 1975–1996 1.9f 1996–1999 2.5 1999–2001 8.3
Source: Nine SEER areas (San Francisco-Oakland, Connecticut, Detroit-Metropolitan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, and Atlanta-Metropolitan).
SEER: Surveillance, Epidemiology, and End Results Program; APC: annual percent change; NOS: not otherwise specified.
a Joinpoint (JP) Regression Program, Version 2.7. Sept. 2003, National Cancer Institute.
b The top 15 cancers were selected based on the sex-specific age-adjusted rate for 1992–2001 for all races combined.
c Joinpoint analyses with up to three joinpoints are based on rates per 100,000 age-adjusted to the 2000 U.S. standard population.
d Annual percent change based on rates that were age-adjusted to the 2000 U.S. standard population using joinpoint regression analysis.
e All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
f The annual percent change is statistically significantly different from zero (two-sided P  0.05).
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ethnic populations except for Hispanic/Latina
women and AI/AN men and women. Similarly, can-
cers of the oral cavity among men and women de-
creased in all populations, except for AI/AN men
and women, API women, and Hispanic/Latina
women. Finally, death rates for cancers of the gall-
bladder decreased among white, API, and Hispanic/
Latina women, and cervical cancer death rates de-
creased in all populations.
Cancer in the white population
Among women, white women had the highest can-
cer incidence rates for all cancer sites combined
(Table 3). The incidence rates for cancers of the
TABLE 2
U.S. Death Rate Trends with Joinpointa Analyses for 1975 through 2001 for the Top 15 Cancers,b All Races
Joinpoint analyses (1975–2001)c
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
All sites
Both sexes 1975–1990 0.5e 1990–1993 0.3 1993–2001 1.1e
Male 1975–1979 1.0e 1979–1990 0.3e 1990–1993 0.4 1993–2001 1.5e
Female 1975–1992 0.5e 1992–2001 0.8e
Top 15 for males
Lung and bronchus 1975–1982 1.8e 1982–1991 0.4e 1991–2001 1.9e
Prostate 1975–1987 0.9e 1987–1991 3.0e 1991–1994 0.6 1994–2001 4.1e
Colon and rectum 1975–1984 0.1 1984–1990 1.4e 1990–2001 2.0e
Pancreas 1975–1986 0.8e 1986–2001 0.3e
Non-Hodgkin lymphoma 1975–1996 2.5e 1996–2001 2.4e
Leukemia 1975–1995 0.2e 1995–2001 0.8e
Urinary bladder 1975–1983 1.4e 1983–1987 2.8e 1987–1993 0.1 1993–2001 0.7e
Esophagus 1975–1985 0.7e 1985–1994 1.2e 1994–2001 0.5e
Stomach 1975–1994 2.1e 1994–2001 3.7e
Liver and intrahepatic bile duct 1975–1986 1.6e 1986–1995 4.0e 1995–2001 1.4e
Kidney and renal pelvis 1975–1991 1.1e 1991–2001 0.1
Brain and other nervous system 1975–1977 4.4 1977–1982 0.4 1982–1990 1.5e 1990–2001 0.7e
Myeloma 1975–1994 1.5e 1994–2001 1.1e
Oral cavity and pharynx 1975–1993 1.9e 1993–2001 3.0e
Melanoma of the skin 1975–1990 2.2e 1990–2001 0.1
Top 15 for females
Lung and bronchus 1975–1982 6.0e 1982–1990 4.2e 1990–1995 1.7e 1995–2001 0.2
Breast 1975–1990 0.4e 1990–2001 2.3e
Colon and rectum 1975–1984 1.0e 1984–2001 1.8e
Pancreas 1975–1984 0.8e 1984–2001 0.1
Ovary 1975–1982 1.2e 1982–1992 0.3 1992–1998 1.2e 1998–2001 0.8
Non-Hodgkin lymphoma 1975–1996 2.2e 1996–2001 2.5e
Leukemia 1975–1980 0.8 1980–2001 0.4e
Corpus and uterus, NOS 1975–1991 1.6e 1991–2001 0.2
Brain and other nervous system 1975–1992 0.9e 1992–2001 1.0e
Stomach 1975–1987 2.8e 1987–1990 0.5 1990–2001 2.6e
Myeloma 1975–1993 1.5e 1993–2001 0.4
Cervix uteri 1975–1982 4.4e 1982–1996 1.6e 1996–2001 3.8e
Liver and intrahepatic bile duct 1975–1987 0.8e 1987–1995 3.8e 1995–2001 0.3
Kidney and renal pelvis 1975–1992 1.3e 1992–2001 0.5
Urinary bladder 1975–1977 2.1 1977–1985 2.2e 1985–2001 0.4e
Source: National Center for Health Statistics public-use data file for the total U.S.
APC: annual percent change; NOS: not otherwise specified.
a Joinpoint Regression Program, Version 2.7. Sept. 2003, National Cancer Institute.
b The top 15 cancers were selected based on the sex-specific age-adjusted rate for 1992–2001 for all races combined.
c Joinpoint analyses with up to three joinpoints are based on rates per 100,000 age-adjusted to the 2000 U.S. standard population.
d Annual percent change based on rates that were age-adjusted to the 2000 U.S. standard population using joinpoint regression analysis.
e The annual percent change is statistically significantly different from zero (two-sided P  0.05).
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TABLE 3
SEER Incidence Rates and Trends for the Top 15 Cancersa by Sex and Race/Ethnicity for 1992–2001
Sex/cancer site
All races Whites Blacks API AI/AN Hispanics/Latinosb
Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC
Male
All sitesc 572.0 1.6d 573.5 1.5d 719.0 1.9d 395.8 1.3d 286.3 3.9d 431.3 1.2d
Prostate 1 180.3 2.5d 1 175.6 2.6d 1 284.6 2.3d 1 105.0 1.9 1 62.9 7.9d 1 143.0 1.1d
Lung and bronchus 2 83.5 2.3d 2 82.2 2.3d 2 124.5 2.6d 2 61.6 1.3d 2 51.7 4.3d 3 47.9 2.7d
Colon and rectum 3 64.5 1.1d 3 64.4 1.2d 3 72.9 0.6 3 56.9 0.7d 3 40.8 2.8 2 48.8 0.5
Urinary bladder 4 36.1 0.1 4 39.7 0.0 5 20.2 0.3 7 16.3 0.1 8 8.9 — 5 18.9 0.6
Non-Hodgkin lymphoma 5 23.7 0.5 5 24.8 0.5 7 18.8 1.5 6 16.7 0.3 7 9.4 — 4 19.4 1.4
Melanoma of the skin 6 20.2 2.7d 6 23.6 3.2d 23 1.3 — 21 1.6 1.7 19 2.2 — 17 4.1 3.4d
Oral cavity and pharynx 7 16.7 2.4d 8 16.5 2.2d 4 21.4 3.4d 8 12.7 2.3 6 12.3 7.8d 11 10.6 3.4d
Leukemia 8 16.3 1.3d 7 17.3 1.3d 11 13.0 1.2 10 9.8 0.1 12 5.3 — 9 11.8 0.9
Kidney and renal pelvis 9 15.3 1.3d 9 15.7 1.4d 8 18.1 1.9 11 8.8 0.4 4 15.0 5.9d 7 14.4 1.4
Stomach 10 13.3 2.3d 11 11.5 2.3d 6 20.0 2.6d 4 23.5 3.5d 5 14.3 — 6 18.8 2.8d
Pancreas 11 12.7 0.4 10 12.4 0.0 9 17.9 2.0d 9 10.8 2.9d 10 7.6 — 10 10.7 1.3
Liver and intrahepatic bile duct 12 8.5 3.2d 15 6.7 3.2d 14 10.7 4.6d 5 20.7 0.8 9 8.7 — 8 13.1 1.9
Brain and other nervous system 13 7.7 0.7 12 8.5 0.5 16 4.7 0.1 14 4.2 0.9 15 3.0 — 14 5.7 0.4
Esophagus 14 7.6 0.5 13 7.3 1.9d 13 12.6 5.8d 12 5.2 1.3 11 5.7 — 13 6.0 0.4
Larynx 15 7.3 3.4d 14 7.2 3.3d 12 12.9 2.9d 16 3.5 2.8 20 2.0 — 15 5.7 1.5d
Myeloma 16 7.0 1.0 16 6.7 0.7 10 13.3 1.7 13 4.2 2.1 13 4.1 — 12 6.4 1.8
Other nonepithelial skine 17 6.3 13.3d 17 6.5 14.2d 15 6.9 10.4d 20 2.0 9.9d 18 2.4 — 16 5.4 19.1d
Thyroid 19 3.6 2.4d 19 3.8 2.8d 20 2.1 0.8 15 3.8 0.7 21 1.9 — 21 2.8 1.8
Gallbladder 29 0.9 2.2 31 0.8 1.7 30 0.8 — 22 1.4 5.7 14 3.0 — 25 1.3 0.2
Female
All sitesc 411.8 0.1 425.1 0.3 401.9 0.4 300.0 0.2 228.7 1.7d 309.4 0.1
Breast 1 132.5 0.6d 1 138.3 0.8d 1 120.3 0.3 1 92.2 1.7d 1 60.4 3.7d 1 88.3 0.7
Lung and bronchus 2 49.2 0.2 2 51.3 0.2 3 53.7 0.5 3 28.3 0.1 3 25.9 3.1d 3 24.4 1.5
Colon and rectum 3 46.6 0.5 3 46.1 0.6 2 56.1 0.0 2 39.0 0.4 2 32.1 0.9 2 32.5 0.1
Corpus and uterus, NOS 4 24.5 0.1 4 26.1 0.1 4 18.0 0.9 4 16.8 1.4d 4 9.9 — 5 16.5 0.5
Non-Hodgkin lymphoma 5 15.4 0.8d 5 16.2 0.8d 7 10.8 2.9d 7 11.1 1.3 10 6.9 — 6 13.3 0.6
Ovaryc 6 14.2 1.0d 7 15.1 0.8d 8 10.3 1.6 9 10.2 0.6 5 9.2 — 7 11.7 1.0
Melanoma of the skin 7 13.0 2.5d 6 15.6 3.2d 29 0.8 — 21 1.3 4.5 19 1.9 — 17 4.1 3.3d
Cervix uteri 8 9.9 2.6d 12 9.4 2.2d 6 12.8 3.1d 8 10.9 4.7d 9 6.9 7.0 4 17.7 3.3d
Pancreas 9 9.9 0.6 11 9.6 0.6 5 14.7 2.5d 10 8.2 2.3d 8 7.1 — 10 9.3 0.4
Leukemia 10 9.6 0.8d 8 10.1 0.5 12 8.1 0.5 12 6.3 2.9d 13 4.4 — 12 7.6 1.3
Thyroid 11 9.5 4.3d 10 9.8 4.8d 15 5.2 3.8d 6 11.4 1.3 12 5.8 2.6 9 9.5 2.5d
Urinary bladder 12 9.2 0.5d 9 9.9 0.4d 13 7.5 0.3 14 4.4 0.2 18 2.1 — 14 5.1 1.1
Kidney and renal pelvis 13 7.6 1.5d 13 7.8 1.4d 11 9.0 2.8d 15 4.1 3.1d 6 8.1 — 11 7.7 3.0d
Oral cavity and pharynx 14 6.7 1.4d 14 6.7 1.5d 14 6.5 2.1 13 5.8 0.2 14 4.0 — 18 4.0 1.5
Stomach 15 6.2 0.9 16 5.1 1.3 10 9.7 0.0 5 13.2 2.7d 7 7.6 — 8 10.2 1.2
Brain and other nervous system 16 5.4 0.6 15 5.9 0.3 18 3.5 0.9 16 2.9 3.6d 20 1.7 — 15 4.5 0.1
Myeloma 17 4.7 0.6 17 4.3 0.7 9 10.3 1.6 17 2.8 2.7 16 3.1 — 16 4.4 0.7
Liver and intrahepatic bile duct 18 3.2 3.3d 19 2.6 3.9d 17 3.6 1.9 11 7.8 0.9 11 5.8 — 13 5.3 4.3d
Gallbladder 23 1.6 1.8d 23 1.6 1.6 24 1.6 1.5 20 1.7 3.8 15 3.8 — 19 4.0 4.2d
Source: 12 SEER areas (San Francisco-Oakland SMSA, Connecticut, Detroit-Metropolitan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, Atlanta-Metropolitan, San Jose-Monterey, Los Angeles, and Alaska).
SEER: Surveillance, Epidemiology, and End Results Program; APC: annual percent change, API: Asian/Pacific Islander; AI/AN: American Indian/Alaska Native; NOS: not otherwise specified.
a Cancers are sorted in descending order according to sex-specific rates for all races. More than 15 cancers may appear under male and female to include the top 15 cancers in every racial and ethnic group.
b Data for Hispanics/Latinos excludes cases diagnosed in Detroit and Hawaii.
c All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
d The annual percent change is statistically significantly different from zero (two-sided P  0.05).
e For other nonepithelial skin for males, 70% is Kaposi sarcoma, 68% for white males and 86% for black males.
–Statistic could not be calculated. The annual percent change is based on fewer than 10 cases for at least 1 year within the time interval.
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female breast and bladder, NHL, melanoma, leuke-
mia, brain cancer, cancer of the corpus uterus (cor-
pus), cancer of the ovary, and cancer of the oral
cavity (females only) were higher in white men and
women than in other racial and ethnic populations,
with melanoma rates being substantially higher. The
rate of bladder cancer in white men (39.7 cases per
100,000 men) was nearly twice that of black men
(20.2 cases). Of the top 15 causes of cancer deaths in
white men and women, rates of lung cancer (women
only), cancer of the ovary, bladder cancer (men
only), NHL, leukemia, brain cancer, and melanoma
were higher than in all other racial and ethnic pop-
ulations (Table 4).
TABLE 4
U.S. Death Rates and Trends for the Top 15 Cancersa by Sex and Race/Ethnicity for 1992–2001
Sex/cancer site
All races Whites Blacks API AI/AN Hispanics/Latinosb
Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC Rank Rate APC
Male
All sites 260.6 1.5c 254.3 1.4c 364.7 1.9c 157.9 1.9c 168.1 0.7 177.1 0.8c
Lung and bronchus 1 81.6 1.9c 1 80.0 1.7c 1 110.7 2.4c 1 41.6 1.7c 1 51.0 1.8 1 40.9 1.4c
Prostate 2 34.6 3.6c 2 31.8 3.7c 2 74.9 2.3c 4 14.7 4.8c 2 22.3 3.9c 2 25.0 2.3c
Colon and rectum 3 26.6 2.1c 3 26.1 2.2c 3 35.0 0.8c 2 16.4 1.8c 3 16.1 2.5 3 18.1 0.1
Pancreas 4 12.3 0.3c 4 12.0 0.1 4 16.6 1.6c 6 8.5 2.2c 7 6.2 1.8 6 9.5 0.5
Non-Hodgkin lymphoma 5 10.5 0.3 5 10.9 0.3 11 7.5 0.3 7 6.8 1.4 8 5.4 5.0c 7 8.1 0.4
Leukemia 6 10.4 0.7c 6 10.7 0.6c 7 9.4 1.1c 8 5.5 1.2 9 5.2 3.9 8 6.7 0.7
Urinary bladder 7 7.7 0.6c 7 8.0 0.5c 13 5.9 2.2c 11 2.9 0.3 13 2.5 1.1 11 4.2 0.8
Esophagus 8 7.6 0.7c 8 7.1 1.7c 6 13.2 4.3c 10 3.7 3.1 10 4.7 0.9 10 4.5 1.2c
Stomach 9 7.2 3.4c 9 6.4 3.6c 5 14.3 2.9c 5 13.0 3.5c 5 7.6 1.2 5 10.1 2.0c
Liver and intrahepatic bile duct 10 6.4 2.0c 12 5.8 2.1c 9 9.1 1.1 3 15.9 0.8 4 7.7 2.5 4 10.1 1.7c
Kidney and renal pelvis 11 6.2 0.1 10 6.2 0.1 12 6.2 0.5 12 2.7 0.8 6 6.7 0.4 9 5.5 0.8
Brain and other nervous system 12 5.7 0.7c 11 6.1 0.6c 15 3.3 0.8c 13 2.3 1.8 14 2.5 3.0 13 3.5 0.6
Myeloma 13 4.8 0.6 13 4.5 0.4 8 9.2 1.0c 14 2.2 1.8 12 3.5 1.8 12 3.8 0.5
Oral cavity and pharynx 14 4.6 2.8c 15 4.2 2.5c 10 8.4 4.4c 9 3.9 2.5c 11 3.7 1.0 14 3.3 4.2c
Melanoma of the skin 15 3.9 0.0 14 4.4 0.2 23 0.5 0.7 20 0.5 3.8 19 0.8 0.3 17 1.1 0.5
Larynx 16 2.7 2.3c 16 2.5 2.2c 14 5.8 2.8c 16 1.0 1.1 15 2.0 5.7 15 2.3 2.0
Soft tissue including heart 17 1.6 0.9 17 1.6 0.9 16 1.6 0.3 15 1.1 3.4 18 0.9 7.0 16 1.2 1.7
Female
All sites 169.9 0.7c 168.6 0.7c 200.1 0.8c 103.0 1.1c 115.1 0.4 112.4 0.3c
Lung and bronchus 1 40.2 0.6c 1 41.0 0.7c 1 39.2 0.4 1 19.2 0.1 1 26.2 1.0 2 14.8 0.1
Breast 2 28.8 2.4c 2 28.3 2.6c 2 36.4 1.2c 2 12.9 0.9 2 14.5 1.8 1 17.9 1.8c
Colon and rectum 3 18.5 1.7c 3 18.0 1.8c 3 24.9 0.7c 3 11.4 2.1c 3 12.0 0.8 3 11.5 0.2
Pancreas 4 9.2 0.1 5 8.9 0.0 4 12.9 0.7c 5 6.7 0.6 4 6.0 0.9 4 7.5 0.1
Ovary 5 9.0 0.6c 4 9.3 0.5c 5 7.6 0.9c 7 4.7 0.5 5 5.1 0.1 5 6.3 0.6
Non-Hodgkin lymphoma 6 6.9 0.5 6 7.2 0.5 11 4.5 0.2 8 4.2 0.6 8 4.0 5.1c 7 5.3 0.1
Leukemia 7 6.0 0.5c 7 6.1 0.4c 10 5.5 0.8c 9 3.4 1.4 10 3.4 1.2 9 4.4 0.4
Corpus and uterus, NOS 8 4.1 0.2 9 3.9 0.2 6 7.0 0.1 11 2.2 0.4 13 2.5 1.8 11 3.2 0.4
Brain and other nervous system 9 3.8 1.1c 8 4.1 1.0c 16 2.3 0.5 12 1.6 3.1 15 1.6 2.1 13 2.5 0.8
Stomach 10 3.5 2.6c 10 3.0 2.8c 7 6.7 2.3c 4 7.7 3.6c 6 4.1 1.4 6 5.5 1.6
Myeloma 11 3.2 0.3 11 2.9 0.3 8 6.6 0.1 13 1.5 0.9 12 2.7 3.1 12 2.7 1.6
Cervix uteri 12 3.1 3.0c 13 2.7 2.5c 9 6.3 5.1c 10 3.0 2.7c 11 3.2 5.9c 10 3.9 2.9c
Liver and intrahepatic bile duct 13 2.9 1.2c 14 2.7 1.1c 12 3.7 1.1 6 6.6 0.4 7 4.1 2.5 8 4.8 2.4c
Kidney and renal pelvis 14 2.8 0.4 12 2.9 0.4 15 2.8 0.1 15 1.2 1.6 9 3.4 1.7 14 2.5 0.6
Urinary bladder 15 2.3 0.6c 15 2.3 0.5 14 3.0 1.0 16 1.1 3.0 18 1.0 3.0 16 1.3 0.4
Esophagus 17 1.8 0.0 18 1.6 0.8c 13 3.5 3.3c 18 0.9 1.9 17 1.1 7.8 18 0.9 2.2
Oral cavity and pharynx 18 1.7 2.5c 17 1.7 2.3c 17 2.2 3.3c 14 1.4 2.7 16 1.2 2.6 19 0.9 0.0
Gallbladder 20 1.0 2.4c 20 0.9 2.5c 19 1.0 1.0 17 1.1 5.8c 14 1.8 2.3 15 1.9 2.7c
Source: National Center for Health Statistics public-use data file for the total U.S.
APC: annual percent change; API: Asian/Pacific Islander; AI/AN: American Indian/Alaska Native; NOS: not otherwise specified.
a Cancers are sorted in descending order according to sex-specific rates for all races. More than 15 cancers may appear under male and female to include the top 15 cancers in every racial and ethnic group.
b Data for Hispanics/Latinos excludes Connecticut, Maine, Maryland, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
c The annual percent change is statistically significantly different from zero (two-sided P  0.05).
–Statistic could not be calculated. The annual percent change is based on fewer than 10 cases for at least 1 year within the time interval.
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Cancer in the black population
Among men, black men had the highest cancer inci-
dence and death rates for all cancer sites combined and
for cancers of the prostate, lung, colon/rectum, oral cav-
ity, stomach (mortality only), kidney (incidence only),
pancreas, esophagus, larynx, and myeloma (Tables 3
and 4). The age-adjusted rate of prostate cancer inci-
dence in black men was 62% higher, and the death rate
was more than twice that of white men, who have the
second highest incidence and death rates of all racial
and ethnic populations studied. Black women had the
highest death rates for all sites combined and the highest
incidence and death rates for the following sites: breast
(mortality only), colon/rectum, lung (incidence only),
kidney (incidence only), oral cavity (mortality only), pan-
creas, esophagus, myeloma, corpus (mortality only), cer-
vix uteri (mortality only), and bladder (mortality only).
The incidence and death rates for myeloma in black men
and women were approximately double the rates for
white men and women. Female breast cancer death
rates were nearly 30% higher in the black population
than in the white population, despite lower incidence
rates.
Cancer in the API population
The incidence rates for cancers of the stomach, liver, and
thyroid (women only) were higher in API populations
than in other racial and ethnic populations. Cancer
death rates were higher for cancers of the liver and
stomach (women only). The liver cancer incidence rate
for males was 20.7 compared with 13.1 for Hispanics/
Latinos, the population with the next highest rate.
Cancer in the AI/AN population
The death rate for kidney cancer in AI/AN men and
women was higher than in other racial and ethnic
populations. Although death rates from cancers of the
liver and stomach among AI/AN men were lower than
for other populations (with the exception of white
men), these sites had ranks of 4 and 5, respectively, for
cancer mortality among AI/AN men. Similarly, al-
though the rates of ovarian cancer incidence in AI/AN
women were lower than in other populations, ovarian
cancer was the fifth most common cancer type in
AI/AN women, the highest ranking for ovarian cancer
in any racial or ethnic population.
Cancer in the Hispanic/Latino population
The incidence rates for cancers of the cervix uteri and
gallbladder and the death rate for cancer of the gall-
bladder were higher in Hispanic/Latina women than
among other racial and ethnic populations. The inci-
dence rate for cancer of cervix uteri in this population
(17.7) ranked 4th and was 38% higher than the rate for
black women (12.8), the population with the next
highest rate.
Changes in Survival Rates over Time
The absolute and proportional changes in survival for
cancer of all sites combined, all ages, was substantially
greater for men than for women, although the current
survival rates generally were similar (Table 5). In men,
cancers that demonstrated a large absolute gain
( 10%) in survival were all sites combined, cancer of
the prostate, colon/rectum cancer, NHL, melanoma,
leukemia, and kidney cancer; survival for cancers of
the bladder, oral cavity, stomach, liver, brain, and
esophagus showed gains of 5–9.9%. In women, can-
cers that demonstrated a large absolute gain ( 10%)
in survival were cancer of the colon/rectum, NHL,
kidney cancer, and breast cancer; survival for cancer
of all cancers combined, bladder cancer, melanoma,
oral cavity cancer, leukemia, stomach cancer, brain
cancer, cancer of the esophagus, and cancer of the
ovary demonstrated gains of 5–9.9%. Improvement in
survival was limited for the most fatal cancers in
adults (a 5-year survival rate of  20%), which in-
cluded cancers of the lung, pancreas, liver, and esoph-
agus. These cancers are characterized by a late stage at
the time of diagnosis and/or relatively poor survival
even when diagnosed at localized stage (Table 6). Sev-
eral sites with high survival rates (larynx and thyroid)
and cancers of the corpus and cervix uteri showed
little or no gain. Between 1975–1979 and 1995–2000,
survival also improved for several less common can-
cers not listed in Table 5, including testicular cancer
(85–96%) and Hodgkin lymphoma (74 – 85%).
Survival rates for childhood cancers demonstrated
some of the largest improvements, with an absolute
survival increase of 20% in boys and 13% in girls
between 1975–1979 and 1995–2000 (Table 5). The
5-year relative survival rates in 1995–2000 varied ac-
cording to type of cancer, from  50% for acute my-
eloid leukemia in boys to  95% for Hodgkin lym-
phoma in both boys and girls.
Stage-Specific Survival and Stage Distributions and
Geographic Variations
For most specific cancers, patients diagnosed at an ear-
lier stage of disease had higher 5-year survival rates than
those diagnosed at more advanced stages in the 9 SEER
areas (Table 6). There were 9 cancer sites in which  50%
of cases were diagnosed at a localized stage, including
the prostate, urinary bladder, melanoma, kidney, larynx,
thyroid, breast, corpus, and cervix uteri. In contrast, the
majority of lung (53%) and ovarian (68%) cancers were
diagnosed at a distant stage.
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The stage distributions for colorectal, breast, cervi-
cal, and prostate cancers are shown by state in Table 7.
The combined stage distributions for the 4 specific can-
cers among these 29 registries showed lower proportions
of early stages and higher proportions of distant and
unknown stages (Table 7) than those reported in the
SEER Program (Table 6). Furthermore, the stage distri-
butions varied by geographic area for each of the four
cancers. The proportion of localized disease ranged from
28.5% in Nebraska to 44.4% in Hawaii for colorectal
cancer, from 56.5% in Wyoming to 70.2% in Hawaii for
female breast cancer, from 44.7% in Arizona to 62.5% in
Utah for cervical cancer, and from 68.1% in Rhode Island
to 95.5% in Utah for prostate cancer. The proportion of
unknown stages of disease also varied by state for each
of the four cancers.
TABLE 5
Trends in SEER 5-Year Relative Survival Ratesa for the Top 15 Cancersb for All Ages and Childhood Cancers, by Sex, 1975–1979 to 1995–2000
Cancer site
Male Female
Survival rate (%) Change (%) Survival rate (%) Change (%)
1975–1979 1995–2000 Absolutec Proportionalc 1975–1979 1995–2000 Absolutec Proportionalc
All ages
All sitesd 42.7 64.0e 21.3 49.9 56.6 64.3e 7.7 13.6
Prostate 70.0 99.3e 29.3 41.9 — — — —
Lung and bronchus 11.6 13.6e 2.0 17.2 16.6 17.2e 0.6 3.6
Colon and rectum 50.3 63.7e 13.4 26.6 52.3 63.1e 10.8 20.7
Urinary bladder 75.7 83.7e 8.0 10.6 70.6 76.2e 5.6 7.9
Non-Hodgkin lymphoma 46.8 57.0e 10.2 21.8 49.9 61.7e 11.8 23.6
Melanoma of the skin 77.5 89.0e 11.5 14.8 86.5 92.2e 5.7 6.6
Oral cavity and pharynx 51.8 57.4e 5.6 10.8 56.1 61.5e 5.4 9.6
Leukemia 34.8 47.0e 12.2 35.1 37.2 45.7e 8.5 22.8
Kidney and renal pelvis 51.8 63.9e 12.1 23.4 51.3 63.9e 12.6 24.6
Stomach 15.2 22.1e 6.9 45.4 17.8 25.4e 7.6 42.7
Pancreas 2.6 4.2e 1.6 61.5 2.5 4.6e 2.1 84.0
Liver and intrahepatic bile duct 2.2 7.7e 5.5 250.0 6.4 9.6e 3.2 50.0
Brain and other nervous system 22.8 32.7e 9.9 43.4 26.0 33.4e 7.4 28.5
Esophagus 4.3 14.2e 9.9 230.2 6.4 14.7e 8.3 129.7
Larynx 66.4 66.7 0.3 0.5 63.5 59.6 3.9 6.1
Breast (female) — — — — 74.9 87.7e 12.8 17.1
Corpus and uterus, NOS — — — — 86.4 84.4e 2.0 2.3
Ovaryd — — — — 37.6 44.0e 6.4 17.0
Cervix uteri — — — — 69.0 72.7e 3.7 5.4
Thyroid 91.4 93.4 2.0 2.2 93.5 97.3e 3.8 4.1
Age 0–19 years (childhood cancers)
All sitesd 57.6 77.1e 19.5 33.9 68.3 81.0e 12.7 18.6
Bone and joint 43.3 71.1e 27.8 64.2 56.5 63.6 7.1 12.6
Brain and ONS 56.8 71.8e 15.0 26.4 60.2 75.3e 15.1 25.1
Hodgkin lymphoma 85.8 96.4e 10.6 12.4 88.2 95.8e 7.6 8.6
Leukemia 44.2 74.5e 30.3 68.6 53.3 77.5e 24.2 45.4
ALL 52.0 82.0e 30.0 57.7 63.5 83.8e 20.3 32.0
AML 22.8 45.5e 22.7 99.6 20.5 54.2e 33.7 164.4
Neuroblastoma 51.6 65.5e 13.9 26.9 56.6 65.7e 9.1 16.1
Non-Hodgkin lymphoma 42.1 78.5e 36.4 86.5 57.9 82.4e 24.5 42.3
Soft tissue 62.4 73.2e 10.8 17.3 69.6 70.8 1.2 1.7
Wilms tumor 72.7 92.2e 19.5 26.8 76.3 91.9e 15.6 20.4
Source: 9 SEER areas (San Francisco-Oakland, Connecticut, Detroit-Metropolitan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, and Atlanta-Metropolitan).
SEER: Surveillance, Epidemiology, and End Results Program; NOS: not otherwise specified; ONS: other nervous system; ALL: acute lymphocytic leukemia; AML: acute myeloid leukemia.
a Survival rates are based on follow-up of patients through 2001.
b Top 15 cancers includes the top 15 cancers for males and the top 15 cancers for females based on the age-adjusted rate for 1992–2001 for all races combined.
c Absolute change refers to 1995–2000 rate minus 1975–1979 rate whereas proportional change refers to the absolute change divided by the 1975–1979 rate.
d All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
e The difference in rates between 1975–1979 and 1995–2000 is statistically significant (P  0.05).
–Survival rate not applicable.
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Survival Rates by Race and Ethnicity
For all cancers combined, cancer-specific survival rates
at 5 years after diagnosis ranged from 53.9% (AI/AN) to
67.6% (non-Hispanic whites) among men and from
57.0% (blacks) to 68.7% (API) among women in the 5
racial/ethnic populations studied (Table 8). For both
men and women, non-Hispanic white and API patients
tended to have higher survival rates than their counter-
parts for the cancer sites examined, except non-Hispanic
white patients, who had the lowest survival rates for
cancer of the brain (33.5% for men and 35.1% for
women) and API patients, who experienced the lowest
survival rates for leukemia (39.1% for men and 38.9% for
women).
Adjusted RRs of cancer death, accounting for age or
age and stage, were calculated using non-Hispanic white
population as the reference group. Except for myeloma
and cancers of the kidney, thyroid, and gallbladder for
both sexes, melanoma and other nonepithelial skin can-
cers for men, and cancer of the liver for women, the
overall test for racial/ethnic differences in risk of cancer
death was statistically significant for each other cancer
site examined and for all cancers combined. The risk of
cancer death in every minority group was statistically
significantly higher than that of non-Hispanic white pa-
tients for all cancers combined, except for API women,
who had a similar risk of cancer death as their non-
Hispanic white counterparts. Black men experienced
9–67% higher adjusted risks of dying of the index cancer
than non-Hispanic white men for 12 of 13 individual
cancer sites with statistically significant racial/ethnic dif-
ferences; black women experienced 7–82% higher ad-
justed risks for 12 of 14 such individual cancers, except
for cancers of the brain (both sexes) and stomach
(women), which were lower. Hispanic white and
AI/AN patients generally had higher risks of dying
from the index cancer than their non-Hispanic
white and API counterparts. Both API men and
women experienced the lowest RRs for each of the
sex-specific major cancers (prostate, female breast,
TABLE 6
SEER 5-Year Relative Survival Ratesa and Stage Distributionb for the Top 15 Cancer Sites,c 1995–2000





















All sitesd 64.1 — — — — 581,649 — — — —
Prostate 99.3 100.0 e 33.5 81.3 96,225 90.2 e 5.2 4.5
Lung and bronchus 15.2 48.8 22.8 3.3 8.7 75,341 16.4 20.3 53.0 10.3
Colon and rectum 63.4 90.5 67.9 9.4 35.2 63,334 37.0 39.0 18.9 5.1
Urinary bladder 81.7 89.7 36.9 5.5 59.0 23,885 85.2 7.9 3.3 3.5
Non-Hodgkin lymphoma 59.1 71.5 63.5 47.7 66.3 24,126 32.0 13.4 45.4 9.2
Melanoma of the skin 90.5 95.8 52.4 16.2 76.1 21,045 87.9 4.4 3.4 4.4
Oral cavity and pharynx 58.7 80.4 50.2 31.6 46.5 13,249 36.4 43.5 11.7 8.4
Leukemia 46.4 — — — — 15,233 — — — —
Kidney and renal pelvis 63.9 90.9 59.7 9.5 31.6 13,092 52.4 19.8 22.0 5.8
Stomach 23.3 59.9 23.9 3.3 12.6 10,067 22.5 31.2 33.3 13.0
Pancreas 4.4 15.2 6.3 1.6 3.8 13,212 7.5 29.3 47.2 15.9
Liver and intrahepatic bile duct 8.3 18.4 6.8 4.0 3.1 6,457 29.5 11.9 35.5 23.1
Brain and other nervous system 33.0 — — — — 8,758 — — — —
Esophagus 14.3 29.3 13.6 3.1 11.0 5,485 26.1 28.4 27.2 18.2
Larynx 65.1 80.0 42.3 37.5 54.5 4,937 61.7 18.3 16.1 3.9
Thyroid 96.5 99.6 95.8 68.3 87.8 9,436 65.4 23.8 7.7 3.1
Breast (females) 87.7 97.5 79.1 20.4 56.7 91,516 63.4 29.7 4.4 2.5
Corpus and uterus, NOS 84.4 95.8 67.0 22.5 56.0 17,250 72.0 16.1 7.5 4.4
Ovaryc 44.0 94.2 77.6 28.5 23.9 9,645 15.0 10.3 68.0 6.6
Cervix uteri 72.7 92.2 55.1 17.2 59.2 6,321 55.2 30.0 8.7 6.1
Source: 9 SEER areas (San Francisco-Oakland, Connecticut, Detroit-Metropolitan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, and Atlanta-Metropolitan).
SEER: Surveillance, Epidemiology, and End Results Program; NOS: not otherwise specified.
a Survival rates are based on follow-up of patients through 2001.
b Cases were staged according to SEER Summary Stage 1977. Cases based on death certificate only and autopsy were excluded.
c Top 15 cancers includes the top 15 cancers for males and the top 15 cancers for females based on the age-adjusted rate for 1992–2001 for all races combined.
d All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
e Localized/regional stages are combined for prostate cases and reported under the “Localized” heading.
–Stage not applicable.
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TABLE 8
SEER 5-Year Cancer-Specific Survival and Stage-Adjusted and Age-Adjusted Relative Risk of Cancer Death by Cancer Type, Race/Ethnicity, and
Sex, 1992–2000




whites Blacks API AI/AN
NH
whites H whites Blacks API AI/AN
Male (Ref.)
All sites 67.6 65.1 62.1 60.5 53.9 1.0 1.16 (1.14–1.18) 1.26 (1.24–1.28) 1.26 (1.23–1.28) 1.69 (1.59–1.79)
Brain and other nervous system 33.5 46.0 45.2 42.6 59.7 1.0 0.97 (0.88–1.07) 0.98 (0.87–1.10) 0.79 (0.68–0.92) 0.77 (0.48–1.24)
Colon and rectum 64.0 60.9 56.1 66.7 62.3 1.0 1.05 (0.99–1.11) 1.26 (1.20–1.32) 0.95 (0.90–1.00) 1.14 (0.95–1.35)
Esophagus 18.9 20.6 13.4 17.4 18.6 1.0 1.05 (0.94–1.17) 1.29 (1.19–1.40) 1.14 (1.01–1.28) 1.13 (0.80–1.60)
Gallbladder 29.1 26.9 39.2 36.2 38.4 1.0 1.20 (0.91–1.60) 1.18 (0.81–1.74) 1.24 (0.90–1.72) 1.26 (0.66–2.41)
Kidney and renal pelvis 66.1 65.4 69.7 62.6 70.2 1.0 1.03 (0.94–1.14) 1.06 (0.95–1.18) 0.96 (0.84–1.09) 1.14 (0.83–1.58)
Larynx 81.1 75.1 72.6 81.8 63.8b 1.0 1.37 (1.13–1.66) 1.44 (1.25–1.65) 0.88 (0.65–1.20) 2.56b (1.21–5.40)
Leukemia 53.3 53.0 46.2 39.1 45.7 1.0 1.37 (1.27–1.48) 1.40 (1.28–1.52) 1.71 (1.56–1.89) 1.43 (1.03–1.99)
Liver and intrahepatic bile duct 12.7 15.1 7.8 15.6 20.1 1.0 1.09 (1.01–1.18) 1.20 (1.10–1.31) 0.91 (0.85–0.98) 1.08 (0.83–1.39)
Lung and bronchus 16.0 14.4 13.7 17.3 14.0 1.0 1.08 (1.04–1.12) 1.09 (1.06–1.11) 0.90 (0.87–0.93) 1.23 (1.10–1.36)
Melanoma of the skin 86.5 77.1 77.7 76.5 80.1 1.0 1.08 (0.88–1.34) 0.88 (0.55–1.41) 1.11 (0.75–1.64) 1.29 (0.53–3.12)
Myeloma 36.2 39.7 40.4 46.6 33.1 1.0 1.00 (0.89–1.13) 1.01 (0.92–1.11) 0.80 (0.68–0.94) 1.25 (0.80–1.94)
Non-Hodgkin lymphoma 63.2 61.6 65.0 55.5 56.1 1.0 1.32 (1.22–1.42) 1.21 (1.10–1.32) 1.32 (1.21–1.45) 1.57 (1.12–2.21)
Oral cavity and pharynx 77.5 73.2 63.3 71.2 60.7 1.0 1.25 (1.09–1.42) 1.67 (1.52–1.83) 1.22 (1.07–1.38) 1.56 (1.15–2.12)
Other nonepithelial skind 97.8 99.4 98.2 98.6 100.0 1.0 0.55 (0.22–1.38) 1.28 (0.63–2.63) 0.92 (0.29–2.97) c
Pancreas 5.6 7.5 5.5 7.6 9.6 1.0 1.08 (1.00–1.16) 1.15 (1.08–1.22) 0.97 (0.90–1.05) 1.07 (0.82–1.41)
Prostate 92.0 90.0 88.3 92.3 83.0 1.0 1.12 (1.05–1.19) 1.31 (1.25–1.36) 0.70 (0.65–0.76) 1.81 (1.46–2.24)
Stomach 34.9 28.0 27.3 32.7 18.8 1.0 1.26 (1.18–1.36) 1.33 (1.24–1.43) 1.10 (1.02–1.18) 1.87 (1.52–2.30)
Thyroid 92.3 92.8 91.5 94.3 96.0 1.0 0.99 (0.68–1.44) 1.15 (0.69–1.90) 0.79 (0.51–1.22) 0.87 (0.28–2.75)
Urinary bladder 85.1 84.0 75.5 84.3 75.5 1.0 1.09 (0.95–1.26) 1.43 (1.27–1.61) 0.86 (0.73–1.01) 1.14 (0.70–1.87)
Female
All sites 67.0 66.8 57.0 68.7 60.4 1.0 1.20 (1.18–1.22) 1.52 (1.50–1.55) 1.01 (0.99–1.03) 1.54 (1.45–1.64)
Brain and other nervous system 35.1 46.2 43.9 45.4 49.2 1.0 1.05 (0.95–1.17) 0.88 (0.78–1.00) 0.75 (0.63–0.89) 0.78 (0.44–1.38)
Breast 87.5 83.0 75.0 89.4 79.6 1.0 1.22 (1.16–1.28) 1.75(1.68–1.82) 0.90 (0.85–0.97) 1.55 (1.32–1.81)
Cervix uteri 77.2 81.1 69.5 78.0 75.8 1.0 0.77 (0.69–0.85) 1.21 (1.09–1.34) 0.83 (0.71–0.96) 0.97 (0.64–1.47)
Colon and rectum 63.4 61.3 57.0 68.2 58.2 1.0 1.05 (0.99–1.11) 1.18 (1.13–1.23) 0.90 (0.85–0.96) 1.38 (1.16–1.64)
Corpus and uterus 86.6 85.4 69.9 87.4 83.2 1.0 1.22 (1.09–1.38) 1.82 (1.66–1.99) 1.08 (0.94–1.24) 1.69 (1.09–2.63)
Gallbladder 25.6 32.3 30.2 27.7 32.3 1.0 1.05 (0.91–1.21) 0.91 (0.73–1.14) 0.89 (0.70–1.13) 0.82 (0.52–1.28)
Kidney and renal pelvis 66.4 69.6 70.1 68.4 64.2 1.0 0.94 (0.83–1.07) 0.99 (0.87–1.12) 0.78 (0.64–0.96) 1.16 (0.83–1.62)
Leukemia 51.7 53.0 43.9 38.9 46.5 1.0 1.33 (1.21–1.45) 1.36 (1.24–1.49) 1.75 (1.57–1.96) 1.48 (1.07–2.06)
Liver and intrahepatic bile duct 15.9 18.5 11.8 14.8 25.0 1.0 1.07 (0.96–1.20) 1.14 (1.00–1.30) 0.99 (0.89–1.11) 0.94 (0.66–1.33)
Lung and bronchus 20.2 18.1 18.1 19.8 17.2 1.0 1.04 (1.00–1.09) 1.07 (1.04–1.11) 0.89 (0.85–0.93) 1.22 (1.06–1.40)
Melanoma of the skin 92.2 86.8 71.5 78.8 80.1 1.0 1.23 (0.97–1.55) 1.82 (1.20–2.77) 1.43 (0.89–2.32) 0.98 (0.41–2.39)
Myeloma 32.2 31.8 35.2 40.5 23.4 1.0 1.08 (0.96–1.23) 1.00 (0.92–1.10) 0.84 (0.70–1.00) 1.43 (0.93–2.20)
Non-Hodgkin lymphoma 62.9 62.1 64.0 64.2 63.0 1.0 1.21 (1.11–1.31) 1.29 (1.17–1.42) 1.09 (0.98–1.21) 1.42 (0.99–2.05)
Oral cavity and pharynx 75.8 76.3 70.6 75.9 69.0 1.0 1.04 (0.86–1.27) 1.32 (1.14–1.54) 1.02 (0.84–1.23) 1.29 (0.73–2.28)
Ovary 43.6 53.2 46.3 57.4 45.5 1.0 1.01 (0.94–1.08) 1.19 (1.10–1.29) 0.96 (0.87–1.07) 1.10 (0.84–1.43)
Pancreas 5.0 8.9 5.4 8.4 c 1.0 1.01 (0.94–1.08) 1.09 (1.03–1.15) 0.87 (0.80–0.94) 1.14 (0.89–1.47)
Stomach 31.0 29.0 32.7 33.0 21.6 1.0 1.12 (1.03–1.22) 0.96 (0.88–1.05) 0.98 (0.90–1.07) 1.53 (1.19–1.97)
Thyroid 96.5 95.6 96.3 94.9 98.1 1.0 1.22 (0.95–1.58) 0.94 (0.64–1.37) 1.24 (0.95–1.63) 1.12 (0.28–4.54)
Urinary bladder 79.1 75.5 62.9 76.1 76.7b 1.0 1.12 (0.93–1.34) 1.38 (1.20–1.58) 0.98 (0.79–1.23) 1.79b (0.67–4.77)
Source: 12 SEER areas (San Francisco-Oakland, Connecticut, Detroit-Metropolitan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, Utah, Atlanta-Metropolitan, San Jose-Monterey, Los Angeles, and AI/AN in
Alaska).
SEER: Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, NH whites: non-Hispanic whites; H whites: Hispanic whites; API: Asian/Pacific Islander; AI/AN: American Indian/Alaska
Native; 95% CI: 95% confidence interval.
a Up to 5 years of follow-up. Using stratified Cox models, the relative risks for all cancers combined are adjusted for age at diagnosis, and those for individual cancer sites are adjusted for age and tumor stage.
P values are  0.05 for the overall test of racial/ethnic differences in the relative risks of cancer deaths using stratified Cox models by cancer site and sex; except for Kidney and renal pelvis, Thyroid, Myeloma, and
Gallbladder for both sexes, for Liver and Intrahepatic bile duct for female, and for Melanoma of the skin and Other nonepithelial skin for male (all have P values  0.06 and are marked with gray background).
b Cohort size  25 (24 for male AI/AN Larynx and 18 for female AI/AN Urinary bladder).
c Statistic could not be calculated for female AI/AN diagnosed with cancer of pancreas because the last patient was censored before the end of 5-year follow-up (censored at 35 months) and for male AI/AN diagnosed
with other nonepithelial skin because none of the 39 patients died of Other nonepithelial skin cancer at the end of 5-year follow-up.
d For male cancer of other nonepithelial skin, nearly 70% were Kaposi sarcoma and, of those who died, 80% had acquired immunodeficiency syndrome (AIDS) as the underlying cause of death. These were not
considered cancer deaths.
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lung, and colon/rectum), with RRs ranging from
0.70 – 0.95. In addition, API patients had the lowest
RRs for cancers of the brain (women), liver (men),
and pancreas (both sexes). However, non-Hispanic
white men and women experienced the highest risks
of brain cancer death whereas API men and women
had the highest risks of leukemia death.
DISCUSSION
Overall Cancer Incidence, Mortality, and Survival Trends
The current study data show considerable progress in
reducing the cancer burden in the U.S. Overall cancer
death rates have continued to decrease since the early
1990s in both men and women and for many of the
top 15 cancer sites, including lung, colon/rectum, and
prostate in men and colon/rectum and breast in
women. Overall incidence rates also have decreased,
although they stabilized when adjusted for a delay in
reporting. Survival rates have increased for many can-
cers over the last 20 years.
The decrease in overall cancer death rates repre-
sents a change from last year’s annual report, when
the declines were reported to have leveled off in the
most recent time period in women and both sexes
combined.6 With the additional data for 2001, it ap-
pears that the declines in mortality rates that began in
the early 1990s are continuing, supporting an earlier
interpretation that the apparent change in trend may
be a consequence of changes in coding rules for un-
derlying cause of death in the ICD-10, which were
implemented with 1999 mortality data and revised
population.25
Changes in incidence may result from changes in
the prevalence of risk factors and/or changes in de-
tection practices due to the introduction or increased
use of screening/diagnostic techniques. Furthermore,
incidence trends can be affected by reporting delay.
The overall trend in incidence for both sexes com-
bined appears to have been heavily influenced by
reporting delay and rapidly changing prostate cancer
trends; prostate cancer decreased quickly between
1992–1995, after a period of rapid increase. When
prostate cancer incidence rates were excluded from
the trend analysis, the incidence rates for both sexes
combined were stable during 1987–2001. Overall inci-
dence rates also became stable between 1995–2001
when adjusted for reporting delay.
The gains in survival rates for all cancer sites com-
bined and for the most common cancers over the last
20 years, which have been accompanied by decreases
in death rates, may reflect improved treatment, earlier
detection of cancers with effective treatments, and
improved supportive and general medical care. How-
ever, the introduction of or improvements in early
detection or diagnostic tests may increase observed
survival rates spuriously by advancing the time of
diagnosis of disease without prolonging life (lead-time
bias), by the preferential detection of slower growing
tumors (length-time bias), or by the detection of in-
dolent cases that never would have been diagnosed in
the absence of such diagnostic techniques (overdiag-
nosis bias).9,26,27 Although examining temporal
changes in disease stage at diagnosis and stage-spe-
cific survival may be helpful in understanding tempo-
ral trends in survival, they must be interpreted with
caution because changes in stage-specific survival, es-
pecially for localized stage disease, also can be af-
fected by lead-time, length-time, and overdiagnosis
biases.9,26,27 In addition, improvements in staging
techniques or changes in staging systems can influ-
ence stage-specific survival.28 Assessing the relative
contribution of changes in disease detection, classifi-
cation, and treatment is difficult when explaining tem-
poral survival changes.
Survival rates for all cancers combined also may
change over time or differ across racial and ethnic
populations because of changes or differences in the
mix of cancers. For example, the absolute change in
survival for cancers of all sites in the last 20 years was
substantially greater for men than for women. Much
of the increase in survival for men reflects the increas-
ing incidence and survival rate for prostate cancer
during the period. When prostate cancer cases were
excluded, the all cancers combined relative survival
rate for men was 37.5% between 1975–1979 and 48.1%
between 1995–2000, an absolute gain of 10% com-
pared with approximately 20% with the inclusion of
prostate cancer. The lower survival rate for men com-
pared with women in the recent period, after the ex-
clusion of prostate cancer, primarily results from a
different mix of cancers, although women have a slight
survival advantage for a number of cancers. The sur-
vival rate for a specific cancer also may be affected if
there is variation by histologic type and the distribu-
tion of histologic types changes over time.
Differences in survival between racial and ethnic
populations may be influenced by stage at diagnosis,
the measurement biases discussed earlier, the preva-
lence of comorbidities, and the quality of cancer treat-
ment and supportive care. Socioeconomic differences
undoubtedly play a role; members of most racial and
ethnic minorities are more likely to be poor, to have a
lower level of income, and to lack health insurance
compared with non-Hispanic white populations.29
Historically, the prevalence of screening for breast,
colorectal, and cervical cancers has been lower for
members of racial and ethnic minorities compared
with non-Hispanic white populations.30 As a result,
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minority populations are more likely to be diagnosed
at a more advanced stage of disease, when treatment
is either not recommended or is less effective.
Differences in cause-specific survival rates by race
and ethnicity may be influenced by differences in
stage and age distribution; however, analyses of the
RR of cancer death controlled for these factors. Even
with control for stage, residual effects of screening,
such as differences in the extent of disease within
stage and lead-time, length-time, and overdiagnosis
biases, may play a role. Other possible explanations
for differential survival after a cancer diagnosis in-
clude socioeconomic barriers to timely and high-qual-
ity cancer care, cultural barriers and beliefs that may
influence the treatment decision, and the presence of
comorbidities.29,31–33 For many cancers, there are lim-
ited or no data available to explain survival differ-
ences, with much of the available data pertaining only
to white and black patients. The limited data available
frequently document differences in the receipt of op-
timal treatment based on socioeconomic status and
race/ethnicity, with little evidence that response to
treatment varies among racial and ethnic groups when
accounting for stage of disease and other important
prognostic variables.33
The following sections describe possible reasons
for temporal trends and variations in the incidence,
mortality, and survival by race and ethnicity for the 4
common cancers and for cancers with an at least 10%
absolute gain in the survival rate over the past 20 years
in either men or women.
Prostate Cancer
The recent increase in prostate cancer incidence most
likely reflects a return to baseline trends after a period
of rapidly increasing, then decreasing, rates due to the
introduction of the prostate-specific antigen (PSA)
test.34 Both PSA-related early detection and improved
treatments may have contributed to the remarkable
decreases in prostate cancer mortality noted since the
early 1990s.6 Reasons for the disproportionately higher
prostate cancer incidence and death rates in black
men compared with other racial ethnic populations
are unknown. Age, race, and family history are the
only well-documented risk factors.35 Although one re-
cent study linked agricultural chemical exposure to
prostate cancer,36 population-attributable risk differ-
ences in chemical exposure are unlikely to explain the
large differences in prostate cancer incidence and
death rates observed between black and white men.
The 5-year relative survival rate for prostate can-
cer increased significantly from 70% in the mid-1970s
to 99% between 1995–2000, the largest absolute in-
crease (29%) reported for any cancer. A shift in the
detection of new prostate cancer cases from distant-
stage to early-stage disease through the widespread
use of PSA testing has been reported37 and most likely
contributed to the improved survival. However, be-
cause a high proportion of men are found to have
clinically occult cancer at autopsy,38,39 it is assumed
that some prostate cancers identified by PSA would
not have otherwise presented as clinical disease.40 The
extent to which overdiagnosis, length-time, and lead-
time biases have contributed to improvements in sur-
vival is unknown, but believed to be substantial.
Improved survival from prostate cancer also may
be due to the dissemination of hormonal therapy for
early-stage and advanced stage disease.41,42 A recent
pooled analysis of prostate cancer randomized trials
found that the 10-year survival rate was significantly
higher in men treated immediately with hormonal
therapy (74%) compared with those who deferred
such treatment (62%).43 Substantial advances in radi-
ation therapy techniques in the past decade also may
have contributed to gains in survival.44 The role of
radical prostatectomy for localized disease has yet to
be clarified.
After controlling for age and stage of diagnosis,
the RR of cancer death once prostate cancer is diag-
nosed is highest for AI/AN men, followed by black and
Hispanic white men; API men have a significantly
lower risk than non-Hispanic white men. Low socio-
economic status, lack of health insurance, and low
literacy rates can delay diagnosis and reduce access to
optimal therapies.45 Treatment differences such as a
higher rate of radical prostatectomy for early-stage
prostate cancer in white patients compared with black
patients have been documented;46 however, the im-
pact on survival differences is unknown.
Lung Cancer
Changing temporal patterns in the occurrence of lung
cancer are closely tied to historic cigarette smoking
patterns, with the regular uptake of smoking and sub-
sequent smoking reductions occurring later in women
compared with men.47 Among men, lung cancer inci-
dence and mortality have been declining since the
early 1980s and 1990s, respectively. In women, inci-
dence rates have declined since 1998 and mortality
rates have stabilized since 1995 for the first time, after
increasing for several decades. This first-time decrease
in the incidence rates in women in the SEER areas
appears to be an early indication of the national trend
because reductions in cigarette consumption started
earlier in some areas covered by SEER compared with
the other parts of the U.S.48
Progress in the treatment of lung cancer has been
extremely limited.49,50 Greater than 50% of cases are
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diagnosed at a distant stage, for which the 5-year
relative survival is only 3.3% (Table 6). Surgical resec-
tion may be curative for early-stage nonsmall cell lung
cancer (NSCLC), with recent clinical studies showing
improved survival with neoadjuvant chemotherapy.49
With the exception of API patients, the RR of dying
from lung cancer after diagnosis was 4 –23% higher in
minority populations compared with non-Hispanic
white patients. Differences in survival between black
and white patients with NSCLC are largely explained
by treatment differences, with 64.0% of black patients
who are diagnosed at an early stage undergoing sur-
gery compared with 76.7% of whites51 and 28% of
black patients diagnosed with metastatic disease re-
ceiving chemotherapy after seeing an oncologist com-
pared with 35% of white patients.52 In addition to
ensuring equal access to high-quality treatment, im-
proved survival from lung cancer may be achieved by
earlier detection. Important research efforts include
the National Lung Screening Trial, which has enrolled
nearly 50,000 current or former smokers in a study to
compare whether screening with spiral computed to-
mography or chest X-rays is better at reducing deaths
from lung cancer (available from URL: http://www.
nci.nih.gov/nlst).
Colorectal Cancer
Decreases in colorectal cancer incidence and mortal-
ity rates have been largely attributed to the detection
and removal of precancerous polyps, the early detec-
tion of tumors through screening, and improved treat-
ments.4,6 They also may reflect the increased use of
hormone replacement therapy in women and antiin-
flammatory drugs, both of which appear to reduce the
risk of colon cancer.53,54 A recent publication found a
decreased risk of colorectal cancer but a more ad-
vanced stage of disease (increased lymph node and
metastatic disease) among women receiving estrogen
and progestin regimens.55 The elevated incidence and
death rates in the black population may reflect cul-
tural and socioeconomic differences in physical inac-
tivity, dietary habits, use of tobacco, and access to and
utilization of preventive services.56
From the mid-1970s until 1995–2000, the 5-year
relative survival rate increased from 52% to 63% in
women and from 50% to 64% in men, an increase that
was second only to prostate cancer. The rate of colo-
rectal screening remains low nationally ( 45% based
on the 2000 National Health Interview survey30) and
the potential benefit with broader utilization has yet to
be achieved. However, the use of colorectal screening
is higher in non-Hispanic white men and women than
in other racial and ethnic populations.
A significant advance in colorectal cancer treat-
ment was the introduction of 5-fluoroucil-based adju-
vant chemotherapy for patients with surgically resect-
able Stage III colon cancer in the late 1980s, which
reduced mortality by as much as 30%.57,58 Lower rates
of adjuvant therapy among black patients59 – 62 may
contribute to differences in cancer survival. Other
studies have documented disparities between black
and non-Hispanic white patients with regard to the
receipt of surgical and radiation treatments for colo-
rectal cancer.62,63
Female Breast Cancer
Recent increases in female breast cancer incidence
reflect the increased use of mammography,6,64 and
perhaps an increased prevalence of obesity and the
use of hormone replacement therapy.64 The steady
decline in female breast cancer mortality since 1990
has been attributed, in part, to early detection6 and
the increased use of hormonal and adjuvant chemo-
therapies65,66 and the resulting improved survival,
which increased by 13% since the mid-1970s.
Mammography screening increased in all seg-
ments of the U.S. population, although rates among
minority populations lagged behind rates in white
women.30 White and API women are more likely to be
diagnosed at a localized stage than women of other
racial and ethnic populations.67 Even when controlled
for age and stage at diagnosis, black, Hispanic white,
and AI/AN women had an increased RR of mortality
after diagnosis compared with white and API women.
Reasons for differential breast cancer survival between
white and black women have been studied exten-
sively. Several studies documented treatment differ-
ences between black and white women,68 –70 and oth-
ers found treatment and survival differences between
black and white patients diminished when controlling
for socioeconomic factors, such as lack of insurance
coverage.71,72 Tumor and clinical characteristics such
as estrogen receptor status, tumor size, tumor stage at
diagnosis, and neutropenia also may influence the
types and courses of treatment and survival,64,73–76
although the differential availability of more biologi-
cally targeted treatment options also may contribute
to variations in outcome.
Non-Hodgkin Lymphoma
NHL incidence trends partly reflect an increase in
acquired immunodeficiency syndrome-associated
NHL cases that began in the early 1980s and decreased
in the 1990s.77 The increased incidence in white com-
pared with black populations in the U.S. precedes the
rise in human immunodeficiency virus (HIV)-related
NHL, and has remained remarkably consistent over
time.18 Recent declines in NHL mortality may reflect
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decreases in HIV-associated NHL incidence rates77
and improved treatments.78
NHL comprises a range of pathologic types with
varying prognoses.79,80 Survival trends are influenced
by the increase in HIV-related NHL cases, which have
a poorer prognosis.80 Nonetheless, modest gains in
overall survival have been observed. Improved treat-
ments for indolent NHL include radiotherapy for
early-stage disease81,82 and single-agent and mul-
tiagent chemotherapy for advanced-stage disease.83– 85
For large cell lymphoma, an aggressive NHL, mul-
tiagent chemotherapy was shown in the 1970s and
1980s to achieve disease remission and long-term,
disease-free survival in 35% of patients.86,87 More re-
cently, rituximab, a monoclonal antibody directed
against the CD20 antigen, was found to have activity
against both indolent and aggressive NHL,88 and au-
tologous bone marrow transplantation was found to
increase survival among patients with recurrent, ag-
gressive NHL.89,90 Although all racial and ethnic mi-
nority groups have a higher RR of cancer death from
NHL once diagnosed compared with non-Hispanic
whites, no published study to date has assessed prog-
nostic or treatment variations that may underlie these
differences.
Melanoma
The continued increase in melanoma incidence rates
may reflect increased recreational sun exposure as
well as early detection, resulting mainly from in-
creased awareness by health providers and the general
public.91 The markedly higher incidence and mortality
for white patients reflects their enhanced susceptibil-
ity to the harmful effects of sun exposure.92 The abso-
lute gain in melanoma survival in males (12%) and
females (6%) may be related both to early detection
and improved treatment. Proportions and rates of
melanomas diagnosed at a localized stage and as thin
lesions have increased in the U.S.91,93 Surgical resec-
tion, the major curative therapy for melanoma at the
current time, has undergone significant improve-
ments as a result of documenting optimal margins
based on the depth of the primary lesion.94 The ben-
efits of immunotherapy (interferon and interleukin-2)
in recurrence-free survival and overall survival have
been demonstrated in clinical trials,95 and the use of
recombinant interleukin-2 for patients with metastatic
melanoma recently was approved.96
Leukemia
The incidence of leukemia was stable for both males
and females between 1975–1995, when rates began to
decline for males only. Leukemia is more common in
white populations than in other racial and ethnic
groups, paralleling international patterns of increased
incidence in Western and Northern Europe, North
America, and Australia. Long-term decreases in leuke-
mia death rates reflect dramatic improvements in sur-
vival from childhood leukemia, as well as modest im-
provements in survival for some leukemia subtypes in
adults. Among children and adults combined, leuke-
mia survival rose from 35.9% in 1975–1979 to 46.4% in
1995–2000, whereas for leukemia patients diagnosed
at age  20 years, relative survival rates improved from
34% to 42%.18 As a result of multiagent chemotherapy
and central nervous system prophylaxis, relative sur-
vival for adult patients with acute lymphocyte leuke-
mia (ALL) has improved from 11% in 1975–1979 to
28% in 1995–2000,18,97,98 whereas survival among
adults with chronic lymphocyte leukemia improved
only slightly from the 1970s to the 1990s (69% vs.
73%).18 Acute myeloid leukemia remains a highly fatal
malignancy, although the 5-year relative survival im-
proved from 6% to 17% over the last 20 years. Com-
bined chemotherapy with daunorubicin and cytara-
bine remains the treatment of choice for most
patients,99 and improvements in survival may be at-
tributed in part to improvements in supportive care,
including the treatment of infections.99 The 5-year
relative survival for patients with chronic myelocytic
leukemia (CML) also has increased. Historic treatment
advances include chemotherapy with hydroxyurea
and busulfan, and chemotherapy combined with in-
terferon-.100 More recent advances include alloge-
neic bone marrow transplant and treatment with ima-
tinib mesylate, which has been demonstrated to be
highly effective in inducing and sustaining disease
remission when used as a first course of treat-
ment.101,102 Survival improvements resulting from
imatinib mesylate are too recent to be reflected in
1995–2000 statistics.
The RR of death among leukemia patients is
markedly higher for all racial and ethnic minority pop-
ulations compared with non-Hispanic white popula-
tions. The lowest survival rates observed in the API
leukemia patients might be attributable to the 62% of
API leukemia patients in SEER areas who were diag-
nosed with the more lethal subtypes of myeloid and
monocytic leukemia compared with 44 –50% of other
racial/ethnic populations. Treatment differences that
may contribute to differential survival by race and
ethnicity have not been studied. In the nine SEER
areas, black, Hispanic, and AI/AN children with ALL
have poorer survival than white and API children;103
other reports have demonstrated that black children
with ALL are more likely to present with unfavorable
prognostic features.104 However, in a single pediatric
cancer hospital in which all patients received the same
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treatment without regard to ability to pay, black and
white children had the same rate of survival and
cure.105
Kidney Cancer
Reasons for the increasing incidence of kidney cancer
are not clear,106 but may reflect newer diagnostic tech-
niques107,108 and an increased prevalence of obe-
sity,109,110 which is a known risk factor for kidney
cancer.111 Despite the rising incidence, mortality rates
have been stable since 1991 for men and since 1992 for
women. Black men and women have the highest inci-
dence rates among all racial and ethnic populations,
but mortality rates are approximately equal for white
and black populations and highest for AI/AN patients.
Reasons for increased mortality among the AI/AN
population are unknown. There is considerable varia-
tion in kidney cancer mortality in AI/AN persons by
region, with death rates being particularly high in the
Northern plains.112 Approximately 50% of cancers of
the kidney are diagnosed at the localized stage, for
which the 5-year relative survival is  90% (Table 6).
Surgery remains the primary treatment, with the ben-
efit of adjuvant chemotherapy and radiotherapy con-
sidered to be unproven.113 Improved survival may re-
sult in part from lowered surgical mortality rates due
to advances in anesthesia and presurgical and post-
surgical management.113 When adjusted for age and
stage of disease, no significant differences in the RRs
of cancer death once diagnosed were noted between
racial and ethnic groups.
Childhood Cancers
Since the introduction of chemotherapy for the treat-
ment of childhood leukemia in the 1940s, the progno-
sis for childhood cancers has improved remarkably,
from almost uniformly fatal before the mid-1960s to a
55% survival rate in the mid-1970s, to  75% survival
in the late 1990s. This improvement has been attrib-
uted to the success of chemotherapy for childhood
ALL and the incorporation of chemotherapy into
treatment regimens that previously relied on surgery
or radiotherapy for common forms of childhood can-
cers such as Wilms’ tumor, lymphoma, and osteosar-
coma.114 Increased survival from childhood cancers
also may be correlated in part with improved quality
of care through the pediatric cancer cooperative
groups. Currently 70% of pediatric cancer patients age
 15 years receive their care in pediatric cancer treat-
ment centers.115
Although the 5-year survival has improved re-
markably for most childhood cancers over the past
two decades, with nearly all children with Hodgkin
lymphoma surviving their disease, the survival rate is
still low ( 50%) for some childhood cancers such as
acute myeloid leukemia, reflecting a need for an im-
proved understanding of the mechanism of resistance
to therapy.116
Age-specific analyses demonstrated that survival
rates did not vary by age for all sites combined, but
some variations were evident for individual sites. For
example, the survival rates for ALL were 91% for pa-
tients ages 1– 4 years but only approximately 60% for
infants and patients ages 15–19 years. This may in part
be related to the lower enrollment rates of adolescents
and young adults in clinical trails compared with that
of children.117 In general, survival rates improved
more for boys than girls, removing much of the ad-
vantage in girls’ overall survival noted between 1975–
1979.
Variations in Disease Stage at Diagnosis by Cancer
Registry
Geographic variation in the stage of disease at diag-
nosis was most evident for cancers of the colon/rec-
tum, cervix, and prostate, whereas much less variation
was noted for female breast cancer. The percentages
in Table 7 are not adjusted for age, which may influ-
ence stage distribution. Other differences in cancer
stage at diagnosis may be related to differences in the
population composition by race, ethnicity,118,119 so-
cioeconomic status,120 –123 and health insurance sta-
tus,124,125 all of which can influence access to and
utilization of cancer screening services. As was dis-
cussed in last year’s Annual Report to the Nation, the
prevalence of mammography and cervical and colo-
rectal cancer screening at recommended intervals also
varies across the states.6
Marked variation among states was noted in the
percentage of unstaged cases for all four cancers.
These variations could be related to differences in
medical practice, varying socioeconomic characteris-
tics in the population, registry operations, or a com-
bination of these factors. It is important to better
understand the reasons for these differences because
inadequate staging may result in suboptimal treat-
ment.
Limitations
There are certain limitations in the data and methods
that may influence the interpretations of the findings
in this report. First, routinely collected statistics re-
garding cancer occurrence, as provided in this analy-
sis, are commonly reported according to the major
racial and ethnic populations—whites, blacks, APIs,
AI/ANs, and Hispanics/Latinos. Such broad racial and
ethnic groupings may mask wide variations in the
cancer burden by country of origin, for example,
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among APIs (China, Japan, Philippines, Vietnam,
etc.)126,127 and Hispanics/Latinos (Spain, Cuba, Puerto
Rico, Mexico, etc.)128,129 and by cultural characteristics
that define other high-risk populations such as white
residents in Appalachia,130 recent immigrants, blacks
in the rural South, and over 560 American Indian
tribes recognized by individual states and the federal
government.112,131–133 Cancer rates for populations
other than whites and blacks may be limited by prob-
lems in ascertaining race/ethnicity information from
basic records (medical records, death certificates, and
census reports).134,135 Furthermore, the assessment of
long-term cancer trends is limited to white and black
populations because annual population counts for
other racial and ethnic populations are not available
prior to 1990.
Second, the survival data and most of the inci-
dence data presented in this report are taken from the
SEER registries. The SEER registries were selected to
be a reasonably representative subset of the U.S. pop-
ulation, with a higher representation of racial and
ethnic minorities. Therefore, cancer statistics gener-
ated from SEER areas may differ in some respects from
cancer statistics throughout the country because SEER
areas tend to have more foreign-born individuals and
be more urban populations compared with non-SEER
areas.136
Third, we used two different statistical methods to
describe cancer trends. A single linear model was used
to describe short-term trends (1992–2001) in cancer
incidence and death rates by race and ethnicity. In
contrast, long-term patterns (1975–2001) for all races
and ethnicities combined were characterized using
the joinpoint method. Analyses of data by these two
approaches may in some circumstances lead to differ-
ent results. For example, the prostate cancer incidence
rate decreased by 2.5% per year from 1992–2001,
whereas in the joinpoint model it increased by 1.4%
per year from 1995–2001, after an 11.4% per year de-
crease from 1992–1995. The joinpoint model is a more
flexible and accurate approach to identify the years in
which significant changes in trends occurred, but can-
not always be employed for analyses of trends by race
and ethnicity because of the limited time period with
available data.
Future Directions
The long-term goals of basic and clinical research,
cancer surveillance, and cancer control are activities
to eliminate suffering and death from cancer. This will
come about by striving to prevent the onset as well as
the progression of cancer; identifying cancers at the
earliest stage of disease; eliminating cancer through
targeted treatments; and controlling cancers that can-
not be eliminated so they become manageable,
chronic diseases.
Considerable reduction in the suffering and death
from cancer in the U.S. could be achieved by reaching
all segments of the population with high-quality pre-
vention, early detection, and treatment services.137
Disparities in access to and quality of care have been
documented throughout the cancer spectrum. For ex-
ample, the uninsured and those with only Medicare or
Medicaid may lack access to effective smoking cessa-
tion therapies.137 Individuals with low incomes, those
without health insurance, and those who immigrated
to the U.S. within the last 10 years have a lower prev-
alence of mammography and colorectal and Papani-
colaou smear testing than other population groups.30
Geographic variations also exist in the utilization of
recommended screening tests6 and in the stage of
disease at diagnosis for cancers that are detectable by
screening (Table 7). In response to the documentation
of healthcare disparities for racial and ethnic minori-
ties and other medically underserved groups, federal
programs targeted at reducing disparities have been
created and strengthened. For example, the Quality of
Cancer Care Committee (QCCC), organized by NCI in
2000, has sponsored several interagency projects to
examine how the best available scientific evidence
concerning intervention effectiveness can inform fed-
eral-level decision making regarding cancer care. In
one QCCC project, three federal agencies (the NCI, the
CDC, and the Health Resources and Services Admin-
istration) are collaborating with the nonprofit Institute
for Healthcare Improvement to enhance screening
and follow-up care for patients with breast, cervical,
and colorectal cancers in community health centers
for the medically underserved.139 The National Breast
and Cervical Cancer Early Detection Program created
by the CDC in 1991 has provided over 4 million
screening examinations to underserved women. How-
ever, estimates are that this program reaches only
12–15% of eligible women nationally.140 In 2000, the
NIH established the National Center on Minority
Health and Health Disparities to lead and coordinate
NIH efforts to improve the health of minority and
medically underserved people. In 2001, the Center to
Reduce Cancer Health Disparities was created within
the NCI to stimulate research to address cancer health
disparities.
There also has been growing recognition of gaps
in the delivery of high-quality cancer care in recent
years.31 In 1999, the National Cancer Policy Board
issued a comprehensive report on the state of the
cancer care system, which concluded that some indi-
viduals with cancer do not receive care known to be
effective for their condition.138 Recommendations in-
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cluded the development and use of evidence-based
guidelines for all aspects of cancer care; the develop-
ment of a core set of quality measures that can be used
to measure and monitor the quality of care; the en-
hancement of services for the uninsured and under-
insured to ensure entry to, and equitable treatment
within, the cancer care system; and research to under-
stand why specific segments of the population do not
receive appropriate care. Partnerships to nurture an
integrated approach to fighting cancer and to ensure
that research discoveries are translated into clinical
and public health interventions that can be delivered
to all who need them have been embraced by many
private and public institutions, several of which have
made commitments to programs and activities that
are building blocks for this effort.139 For example, the
NAACCR is actively involved in extending its standard-
ization activities beyond the cancer registry commu-
nity to foster and contribute to a national health in-
formation structure.
In addition to the better application of existing
knowledge, leaders in the scientific community fore-
cast an era of unprecedented progress in cancer re-
search through applying knowledge of the molecular
and cellular mechanisms that underlie the initiation
and progression of cancer. Areas of particular interest,
highlighted in the NCI’s research priorities, include
seven strategic priority areas: molecular epidemiology;
integrated cancer biology; the strategic development
of cancer interventions; prevention, early detection,
and prediction; an integrated clinical trials system;
overcoming health disparities; and bioinformatics.141
The development of imatinib mesylate for the treat-
ment of CML is an example of a treatment break-
through resulting from understanding the molecular
abnormality involved in a particular type of cancer.100
In addition to treatment advances, a better under-
standing of the basis of cancer has led to more effec-
tive prevention strategies, the development of im-
proved tests for early detection, more precise
diagnostic methods, and more powerful treatment ap-
proaches. Transdisciplinary research efforts have the
potential to enhance our understanding of the inter-
action of genetic and environmental risk factors for
tobacco addiction and obesity, leading to the im-
proved prevention and treatment of the major cancer
risk factors in the U.S. population. However, for re-
search advances to impact cancer incidence and death
rates, the translation of research discoveries to the
widespread and equitable delivery of preventive and
clinical services must be expedited.
In the 21st century, cancer surveillance will play a
critical role in monitoring the nation’s progress
against cancer. The Annual Report to the Nation is just
one facet of ongoing collaborations among the ACS,
the CDC’s NPCR and NCHS, the NCI’s SEER Program,
and the NAACCR. Through collaborative and coordi-
nated initiatives and programs, these organizations
are working to improve the comprehensiveness and
quality of data used to focus cancer control efforts and
track progress against cancer. In the future, the inte-
grated and efficient exchange of standardized infor-
mation among clinical, administrative, and public
health data systems will enable better assessments of
these successes in all populations and in all areas of
the U.S.
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